Skip to main content

06-06-2021 | ASCO 2021 | Conference coverage | News

News in brief

PACIFIC at 5 years shows ‘robust and sustained’ OS benefit with durvalumab

Author: Lynda Williams


medwireNews: Five-year findings from the PACIFIC trial for patients with unresectable stage III non-small-cell lung cancer (NSCLC) continue to show survival benefits with 1 year of durvalumab therapy versus placebo after platinum-based chemoradiotherapy.

David Spigel (Sarah Cannon Research Institute, Nashville, Tennessee, USA) told delegates at the 2021 ASCO Annual Meeting that the PD-L1 inhibitor study update demonstrated “robust and sustained” overall survival (OS) and “durable” progression-free survival (PFS), following on from the initial OS and PFS benefits reported.

At data cutoff in January 2021, 55.5% of participants given durvalumab and 65.4% of placebo-treated patients had died. There was a significant OS benefit found for durvalumab, with a hazard ratio (HR) for death of 0.72.

PFS also significantly favored durvalumab use, with a HR of 0.55. In all, 33% of treated patients were alive and free from disease versus 19% of controls, and updated OS and PFS subgroup analyses “were consistent with the results reported at the time of the primary analysis,” the presenter said.

“This establishes a new benchmark for the standard of care in the unresectable stage III non-small-cell lung cancer setting,” Spigel concluded.

“The PACIFIC regimen is being investigated in combination with different chemoradiotherapy regimens as well as with other agents following chemoradiotherapy.”

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

2021 ASCO Annual Meeting; 4–8 June


New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.